novo nordisk has reduced the price of wegovy to $499 per month for patients without insurance coverage, aiming to improve accessibility after the end of the semaglutide shortage indicated by the fda. The move mirrors similar initiatives by eli lilly. Experts suggest the price is still high, maintaining pressure on novo nordisk regarding drug affordability.

novo nordisk announced a reduction in the price of wegovy for uninsured patients.

wegovy, a weight-loss drug by novo nordisk, will now be priced at $499 for cash-paying patients.

eli lilly has launched a similar cash-pay program for their weight-loss drug Zepbound.

The fda declared an end to the shortage of semaglutide, enabling pricing changes from manufacturers.

A professor who commented on the demand for lower-cost weight-loss options.